AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16571160 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham feeding (MSF) with linoleic oil
Number of subjects: 36
Study 16571160 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified sham feeding (MSF) with oleic oil
Number of subjects: 36
Study 16571160 — intervention group
Group type: COMPARATOR
Intervention: Water ingestion
Number of subjects: 36
Study 12610718 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of 30 mg/day aripiprazole with simultaneous immediate discontinuation of current antipsychotic
Number of subjects: 0
Study 12610718 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate initiation of 30 mg/day aripiprazole while tapering off current antipsychotic over 2 weeks
Number of subjects: 0
Study 12610718 — intervention group
Group type: EXPERIMENTAL
Intervention: Up-titrating aripiprazole to 30 mg/day over 2 weeks while simultaneously tapering off current antipsychotic
Number of subjects: 0
Study 10639540 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin E daily from natural sources
Number of subjects: 9541
Study 10639540 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 9541
Study 9185732 — intervention group
Group type: EXPERIMENTAL
Intervention: Multihole fine-needle aspiration (FNA) biopsy
Number of subjects: 88
Study 9185732 — intervention group
Group type: COMPARATOR
Intervention: Single-hole fine-needle aspiration (FNA) biopsy
Number of subjects: 88
Study 1347973 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% apraclonidine hydrochloride with 16-microliters drop size
Number of subjects: 0
Study 1347973 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% apraclonidine solution
Number of subjects: 0
Study 1347973 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation with hydroxypropylmethylcellulose
Number of subjects: 0
Study 1347973 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations with hydroxypropylmethylcellulose or lysolecithin
Number of subjects: 0
Study 1347973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3157894 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drug (NSAID)
Number of subjects: 112
Study 3157894 — intervention group
Group type: COMPARATOR
Intervention: Conservative physiotherapy
Number of subjects: 112
Study 3157894 — intervention group
Group type: COMPARATOR
Intervention: Manipulative physiotherapy
Number of subjects: 112
Study 31919989 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib (tyrosine-kinase inhibitor)
Number of subjects: 1061
Study 30020209 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple suicide attempts
Number of subjects: 0
Study 30020209 — intervention group
Group type: COMPARATOR
Intervention: Single suicide attempts
Number of subjects: 0
Study 28843718 — intervention group
Group type: EXPERIMENTAL
Intervention: PerClot®
Number of subjects: 51
Study 28843718 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 51
Study 25447355 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital cooling with a surface cooling pad for 24 hours
Number of subjects: 110
Study 25447355 — intervention group
Group type: COMPARATOR
Intervention: In-hospital cooling for 24 hours
Number of subjects: 110
Study 24035211 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nifedipine along with conventional treatment
Number of subjects: 90
Study 24035211 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine and conventional treatment
Number of subjects: 90
Study 24035211 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 90
Study 21389845 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint‐induced movement therapy (3 hrs/day, 5 days/wk for 4 weeks)
Number of subjects: 20
Study 21389845 — intervention group
Group type: COMPARATOR
Intervention: General upper limb exercises (3 hrs/day, 5 days/wk for 4 weeks)
Number of subjects: 20
Study 18420851 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 1.25 mg (group D)
Number of subjects: 400
Study 18420851 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg (group H)
Number of subjects: 400
Study 18420851 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg (group Dx)
Number of subjects: 400
Study 18420851 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg plus Dexamethasone 5 mg (group H + Dx)
Number of subjects: 400
Study 18420851 — intervention group
Group type: COMPARATOR
Intervention: Saline (group S)
Number of subjects: 400
Study 16838151 — intervention group
Group type: EXPERIMENTAL
Intervention: POC aPTT
Number of subjects: 126
Study 16838151 — intervention group
Group type: COMPARATOR
Intervention: Lab aPTT
Number of subjects: 126
Study 14500439 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led education and direct access service
Number of subjects: 107000
Study 11023502 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusions (DLI) - bulk-dose (n = 34) or escalating-dose (n = 32) regimen
Number of subjects: 66
Study 11023502 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor lymphocyte infusions (DLI)
Number of subjects: 66
Study 11023502 — intervention group
Group type: COMPARATOR
Intervention: No intervention (failure to achieve molecular remission)
Number of subjects: 66
Study 8777103 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (1 MAC end-tidal concentration)
Number of subjects: 40
Study 8777103 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1 MAC end-tidal concentration)
Number of subjects: 40
Study 1505611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (high dose)
Number of subjects: 0
Study 1505611 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (low dose)
Number of subjects: 0
Study 1505611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (high dose)
Number of subjects: 0
Study 1505611 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (low dose)
Number of subjects: 0
Study 1505611 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine (high dose)
Number of subjects: 0
Study 1505611 — intervention group
Group type: EXPERIMENTAL
Intervention: Triprolidine (low dose)
Number of subjects: 0
Study 1505611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6671847 — intervention group
Group type: EXPERIMENTAL
Intervention: Aversion therapy with covert imagery and electric shock
Number of subjects: 0
Study 6671847 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30689727 — intervention group
Group type: EXPERIMENTAL
Intervention: WHEY diet (N = 10; 0.90 ± 0.01 g protein/kg/day)
Number of subjects: 20
Study 30689727 — intervention group
Group type: COMPARATOR
Intervention: MIXED diet (N = 10; 0.97 ± 0.01 g protein/kg/day)
Number of subjects: 20
Study 30689727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 20
Study 28665227 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental affect (feeling good/bad)
Number of subjects: 59
Study 28665227 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 59
Study 26137923 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and self-regulation coaching intervention (1 motivational interview and 2 self-regulation coaching sessions)
Number of subjects: 78
Study 26137923 — intervention group
Group type: COMPARATOR
Intervention: Patient-education session (control group)
Number of subjects: 78
Study 26137923 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing and self-regulation coaching intervention
Number of subjects: 78
Study 24678955 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib (160 mg once daily)
Number of subjects: 15828
Study 24678955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15828
Study 22161025 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) for 8 weeks
Number of subjects: 75
Study 22161025 — intervention group
Group type: COMPARATOR
Intervention: Social support group
Number of subjects: 75
Study 20954778 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-counseling intervention (TC; n = 228)
Number of subjects: 434
Study 20954778 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC; n = 206)
Number of subjects: 434
Study 20954778 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-counseling intervention (TC)
Number of subjects: 434
Study 20954778 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 434
Study 17050593 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza virus vaccine (LAIV)
Number of subjects: 0
Study 17050593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine (TIV)
Number of subjects: 0
Study 17050593 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15893877 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentences with subject-verb agreement violation
Number of subjects: 0
Study 15893877 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentences with word category violation
Number of subjects: 0
Study 15893877 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentences with combined violations (word category and subject-verb agreement)
Number of subjects: 0
Study 11956775 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanastomotic stent with multiple holes
Number of subjects: 31
Study 11956775 — intervention group
Group type: COMPARATOR
Intervention: No upper system drainage (Control)
Number of subjects: 31
Study 11325444 — intervention group
Group type: EXPERIMENTAL
Intervention: Xialine (a xanthan gum‐based saliva substitute)
Number of subjects: 30
Study 11325444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9068813 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of killed Mycobacterium vaccae as immunotherapy after 1 month of treatment
Number of subjects: 102
Study 9068813 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 102
Study 9068813 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (M. vaccae)
Number of subjects: 102
Study 8439253 — intervention group
Group type: EXPERIMENTAL
Intervention: New technique for measuring stretchability of RFM with pelvic tilt analysis
Number of subjects: 71
Study 8439253 — intervention group
Group type: COMPARATOR
Intervention: Commonly used clinical method for measuring stretchability of RFM
Number of subjects: 71
Study 8439253 — intervention group
Group type: COMPARATOR
Intervention: X-ray measurements for pelvic tilt analysis
Number of subjects: 71
Study 8439253 — intervention group
Group type: COMPARATOR
Intervention: Electronic goniometer for measuring pelvic tilt
Number of subjects: 71
Study 2894973 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 2.5mg bid
Number of subjects: 109
Study 2894973 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5mg bid
Number of subjects: 109
Study 2894973 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10mg bid
Number of subjects: 109
Study 2894973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 31493382 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor skill-based training (6 sessions, 60 minutes total, including two 5-minute blocks of wheelchair propulsion training)
Number of subjects: 34
Study 31493382 — intervention group
Group type: COMPARATOR
Intervention: Active control group (dose-matched uninstructed practice)
Number of subjects: 34
Study 31493382 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (no training or practice)
Number of subjects: 34
Study 28901216 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (3g daily)
Number of subjects: 14
Study 28901216 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (25000 IU every two weeks)
Number of subjects: 14
Study 28901216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 27300158 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal ultrasound assessment
Number of subjects: 90
Study 27300158 — intervention group
Group type: COMPARATOR
Intervention: Digital vaginal examination
Number of subjects: 90
Study 24480515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.71mg/kg
Number of subjects: 8
Study 24480515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.41mg/kg
Number of subjects: 8
Study 24480515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (both doses)
Number of subjects: 8
Study 24480515 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (2mg)
Number of subjects: 8
Study 24480515 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and 24h postinfusion assessments
Number of subjects: 8
Study 23564399 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic diary data monitoring
Number of subjects: 169
Study 20090366 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin infusion
Number of subjects: 48
Study 20090366 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 48
Study 18247194 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 26
Study 18247194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 15758009 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus temozolomide
Number of subjects: 573
Study 15758009 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 573
Study 14522730 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (400 mL, 2.5 mmol chlorogenic acid/L)
Number of subjects: 9
Study 14522730 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (400 mL, 2.5 mmol chlorogenic acid/L)
Number of subjects: 9
Study 14522730 — intervention group
Group type: COMPARATOR
Intervention: Control (400 mL water)
Number of subjects: 9
Study 10556612 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening Span Test (LST) conditions
Number of subjects: 0
Study 10556612 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 8908227 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 8
Study 8908227 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 8
Study 1852471 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin 300 u/kg body weight intramuscularly once daily for 3 consecutive days
Number of subjects: 62
Study 1852471 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 0.5 mg/kg body weight intravenously, three times daily for three consecutive days
Number of subjects: 62
Study 1852471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no dexamethasone nor heparin)
Number of subjects: 62
Study 31247558 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-computer interface (BCI)
Number of subjects: 19
Study 31247558 — intervention group
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation coupled BCI (tDCS-BCI)
Number of subjects: 19
Study 30376857 — intervention group
Group type: EXPERIMENTAL
Intervention: OncoActive intervention (computer-tailored PA advice, pedometer)
Number of subjects: 478
Study 26830678 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4-VL (clinical monitoring, quarterly CD4 cell counts, and quarterly VL testing)
Number of subjects: 1211
Study 26830678 — intervention group
Group type: COMPARATOR
Intervention: CD4-only (clinical monitoring plus quarterly CD4 cell counts)
Number of subjects: 1211
Study 24882606 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided posterior TAP block using 15 mL of 0.375% ropivacaine on each side
Number of subjects: 60
Study 24882606 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcostal TAP block with 15 mL of 0.375% ropivacaine on each side
Number of subjects: 60
Study 24882606 — intervention group
Group type: COMPARATOR
Intervention: Standard general anesthesia
Number of subjects: 60
Study 22211091 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline (NS)
Number of subjects: 90
Study 22211091 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's
Number of subjects: 90
Study 22211091 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmalyte
Number of subjects: 90
Study 20663207 — intervention group
Group type: EXPERIMENTAL
Intervention: APC (24 μg/kg/hour for 96 hours)
Number of subjects: 32
Study 20663207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (similar infusion rate for 96 hours)
Number of subjects: 32
Study 20663207 — intervention group
Group type: EXPERIMENTAL
Intervention: APC
Number of subjects: 32
Study 20663207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17255885 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral application of white noise
Number of subjects: 18
Study 17255885 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 18
Study 15854388 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg budesonide turbuhaler by inhalation every night (Group A)
Number of subjects: 52
Study 15854388 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone 5 mg/d and theophyllin control release tablet 0.2 g twice daily, as well as ventolin aerosol inhalation 200 microg three times daily during asthmatic attack (Group B)
Number of subjects: 52
Study 15854388 — intervention group
Group type: COMPARATOR
Intervention: Theophyllin control release tablet 0.2 g twice daily and ventolin aerosol inhalation (200 microg/d) during asthmatic attack (Group C)
Number of subjects: 52
Study 15854388 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone and theophyllin (Group B)
Number of subjects: 52
Study 15854388 — intervention group
Group type: COMPARATOR
Intervention: Theophyllin and ventolin (Group C)
Number of subjects: 52
Study 12204929 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive case management for a minimum of 12 months
Number of subjects: 595
Study 12204929 — intervention group
Group type: COMPARATOR
Intervention: Overall reduced case-load size
Number of subjects: 595
Study 9659133 — intervention group
Group type: EXPERIMENTAL
Intervention: Barium enema examinations performed by radiographers
Number of subjects: 1000
Study 9659133 — intervention group
Group type: COMPARATOR
Intervention: Barium enema examinations performed by radiologists
Number of subjects: 1000
Study 7650123 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting dose of two ampoules (150 IU) of human menopausal gonadotrophin (HMG) for 7 days (Group 1)
Number of subjects: 151
Study 7650123 — intervention group
Group type: COMPARATOR
Intervention: Starting dose of three ampoules (225 IU) of human menopausal gonadotrophin (HMG) for 7 days (Group 2)
Number of subjects: 151
Study 7650123 — intervention group
Group type: COMPARATOR
Intervention: Starting dose of three ampoules (225 IU) of human menopausal gonadotrophin (HMG) for 7 days (Group 3)
Number of subjects: 151
Study 2695883 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis
Number of subjects: 50
Study 2695883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 79708 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens with rifampicin throughout 4 months
Number of subjects: 5
Study 79708 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens with rifampicin for only the first 2 months
Number of subjects: 5
Study 79708 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of pyrazinamide in the second 2 months
Number of subjects: 5
Study 79708 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of streptomycin from the first 2 months
Number of subjects: 5
Study 79708 — intervention group
Group type: EXPERIMENTAL
Intervention: All five regimens
Number of subjects: 5
Study 30563789 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual (SL) delivery of double mutant heat-labile toxin LTR192G/L211A (dmLT) at doses of 1-50 µg
Number of subjects: 80
Study 30563789 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual (SL) delivery of dmLT at doses of 25 or 50 µg
Number of subjects: 80
Study 30563789 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual (SL) delivery of dmLT (3 doses at days 1, 15, and 29)
Number of subjects: 80
Study 30563789 — intervention group
Group type: EXPERIMENTAL
Intervention: oral administration of dmLT
Number of subjects: 80
Study 30563789 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual (SL) and oral routes of dmLT
Number of subjects: 80
Study 28522637 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia
Number of subjects: 90
Study 28522637 — intervention group
Group type: COMPARATOR
Intervention: Conscious Sedation
Number of subjects: 90
Study 25857665 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT), 50 mL via enema from healthy anonymous donors, once weekly for 6 weeks.
Number of subjects: 75
Study 25857665 — intervention group
Group type: COMPARATOR
Intervention: Placebo (50 mL water enema), once weekly for 6 weeks.
Number of subjects: 75
Study 25857665 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 75
Study 23686372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg (escalated to 300 mg at 2 weeks)
Number of subjects: 71
Study 23686372 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 23686372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren in ACEI/ARB subgroup
Number of subjects: 71
Study 23686372 — intervention group
Group type: COMPARATOR
Intervention: Placebo in ACEI/ARB subgroup
Number of subjects: 71
Study 21712735 — intervention group
Group type: EXPERIMENTAL
Intervention: Body fat‐muscular condition
Number of subjects: 208
Study 21712735 — intervention group
Group type: EXPERIMENTAL
Intervention: Central adiposity‐muscular condition
Number of subjects: 208
Study 21712735 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and time elapsed since menopause
Number of subjects: 208
Study 21712735 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal metabolic rate
Number of subjects: 208
Study 19297248 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (6 g daily)
Number of subjects: 1400
Study 19297248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1400
Study 17708609 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum IL-18 levels (>= 10(5) pg/mL)
Number of subjects: 70